Join the conversation:

At Halozyme, we are dedicated to bringing innovative therapies and breakthrough treatments to patients, their caregivers and their families. Partnering is at the core of our business strategy. We enter into collaborations with biotechnology and pharmaceutical companies to help improve their existing products, to advance the development and commercialization of our partners’ new products, as well as to supplement our own internal pipeline. We currently have technology licensing agreements for our proprietary rHuPH20 enzyme technology with Hoffman-La Roche, Pfizer and Baxter Healthcare. These partnerships generate funding for our company through licensing fees and development milestones. We also participate in the future success of these programs through commercial milestone and royalty payments.

Whether through strategic alliances, technology licensing, or research collaborations, our partnering approach is based on a flexible and creative methodology that is open to new deal structures. Our desire is to build effective and mutually beneficial relationships that generate value in excess of what each partner could have accomplished on their own.

Expanding our pipeline through collaboration with leading biopharmaceutical companies is a mainstay of Halozyme’s business strategy.

If your organization is interested in establishing a strategic partnership with Halozyme Therapeutics, please email David Tomasso.